131 related articles for article (PubMed ID: 11472266)
1. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides.
Shih C; Teicher BA
Curr Pharm Des; 2001 Sep; 7(13):1259-76. PubMed ID: 11472266
[TBL] [Abstract][Full Text] [Related]
2. Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts.
Teicher BA; Forler P; Menon K; Phares V; Amsrud T; Shih C
In Vivo; 2000; 14(4):471-80. PubMed ID: 10945160
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of cryptophycins: effect of infusion time and combination studies.
Menon K; Alvarez E; Forler P; Phares V; Amsrud T; Shih C; Al-Awar R; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(2):142-9. PubMed ID: 10972484
[TBL] [Abstract][Full Text] [Related]
4. Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells.
Lu K; Dempsey J; Schultz RM; Shih C; Teicher BA
Cancer Chemother Pharmacol; 2001; 47(2):170-8. PubMed ID: 11269744
[TBL] [Abstract][Full Text] [Related]
5. Three new cryptophycins from Nostoc sp. GSV 224.
Subbaraju GV; Golakoti T; Patterson GM; Moore RE
J Nat Prod; 1997 Mar; 60(3):302-5. PubMed ID: 9090872
[TBL] [Abstract][Full Text] [Related]
6. Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Liang J; Moore RE; Moher ED; Munroe JE; Al-awar RS; Hay DA; Varie DL; Zhang TY; Aikins JA; Martinelli MJ; Shih C; Ray JE; Gibson LL; Vasudevan V; Polin L; White K; Kushner J; Simpson C; Pugh S; Corbett TH
Invest New Drugs; 2005 Jun; 23(3):213-24. PubMed ID: 15868377
[TBL] [Abstract][Full Text] [Related]
7. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
[TBL] [Abstract][Full Text] [Related]
8. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
[TBL] [Abstract][Full Text] [Related]
9. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Al-Awar RS; Ray JE; Schultz RM; Andis SL; Kennedy JH; Moore RE; Liang J; Golakoti T; Subbaraju GV; Corbett TH
J Med Chem; 2003 Jul; 46(14):2985-3007. PubMed ID: 12825938
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
Panda D; DeLuca K; Williams D; Jordan MA; Wilson L
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9313-8. PubMed ID: 9689077
[TBL] [Abstract][Full Text] [Related]
11. Interaction of cryptophycin 1 with tubulin and microtubules.
Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
[TBL] [Abstract][Full Text] [Related]
12. The cryptophycins: their synthesis and anticancer activity.
Eggen M; Georg GI
Med Res Rev; 2002 Mar; 22(2):85-101. PubMed ID: 11857635
[TBL] [Abstract][Full Text] [Related]
13. Efficient synthesis of cryptophycin-52 and novel para-alkoxymethyl unit A analogues.
Eissler S; Bogner T; Nahrwold M; Sewald N
Chemistry; 2009 Oct; 15(42):11273-87. PubMed ID: 19760734
[TBL] [Abstract][Full Text] [Related]
14. Novel cryptophycin antitumor agents: synthesis and cytotoxicity of fragment "B" analogues.
Patel VF; Andis SL; Kennedy JH; Ray JE; Schultz RM
J Med Chem; 1999 Jul; 42(14):2588-603. PubMed ID: 10411479
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity.
Al-Awar RS; Corbett TH; Ray JE; Polin L; Kennedy JH; Wagner MM; Williams DC
Mol Cancer Ther; 2004 Sep; 3(9):1061-7. PubMed ID: 15367700
[TBL] [Abstract][Full Text] [Related]
16. Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.
Weiss C; Figueras E; Borbely AN; Sewald N
J Pept Sci; 2017 Jul; 23(7-8):514-531. PubMed ID: 28661555
[TBL] [Abstract][Full Text] [Related]
17. Recent approaches for the synthesis of modified cryptophycins.
Weiss C; Sammet B; Sewald N
Nat Prod Rep; 2013 Jul; 30(7):924-40. PubMed ID: 23732943
[TBL] [Abstract][Full Text] [Related]
18. Preclinical anticancer activity of cryptophycin-8.
Corbett TH; Valeriote FA; Demchik L; Polin L; Panchapor C; Pugh S; White K; Knight J; Jones J; Jones L; LoRusso P; Foster B; Wiegand RA; Lisow L; Golakoti T; Heltzel CE; Ogino J; Patterson GM; Moore RE
J Exp Ther Oncol; 1996 Mar; 1(2):95-108. PubMed ID: 9414393
[TBL] [Abstract][Full Text] [Related]
19. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
[TBL] [Abstract][Full Text] [Related]
20. Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent.
Ghosh AK; Swanson L
J Org Chem; 2003 Dec; 68(25):9823-6. PubMed ID: 14656116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]